December 5, 2013

New Data Support Flexibility in Timing of Administration for Sanofi’s Lyxumia®

Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal

 

New Data Support Flexibility in Timing of Administration for Sanofi’s Lyxumia®
Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal

Paris, France – December 5, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) announced today the results of a 24-week Phase IIIb clinical study showing that Lyxumia® (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or the main meal of the day. These results indicate that lixisenatide can effectively lower blood sugar at either time of administration.